Status:
RECRUITING
Prostatic Size Reduction Following of Leuprorelin Acetate
Lead Sponsor:
Consorci Sanitari de Terrassa
Conditions:
Prostate Cancer Adenocarcinoma
Prostate Adenocarcinoma
Eligibility:
MALE
18-95 years
Brief Summary
To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.
Detailed Description
Prostate cancer (PC) is the most common tumor in men worldwide, including our country, with an incidence of 34,413 cases in 2020 (70.6 per 100,000 inhabitants) . The elevation of Prostate-Specific Ant...
Eligibility Criteria
Inclusion
- Man with Prostate positive biopsy. Able to Ssgned informed consent form. Need of hormonal treatment before start of radiotherapy
Exclusion
- Patients With prostate size of less than 20 cc at diagnosis. Patients With Positive lymph nodes or metastatic prostate cancer disease on imaging studies.
- Patients with Previous pelvic radiation therapy.
Key Trial Info
Start Date :
February 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06184464
Start Date
February 2 2024
End Date
December 15 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Terrassa
Terrassa, Barcelona, Spain, 08225